Understanding EU Regulations for Drug Device Combination Products

The healthcare industry is undergoing a significant transformation, with an increasing number of treatments relying on advanced drug device combination products. These products, which merge medicinal substances with medical devices, play a crucial role in modern medicine—ranging from pre-filled syringes to drug-eluting stents. While they offer immense benefits for patient care, they also introduce regulatory complexities, especially in the European Union (EU), where stringent standards ensure safety and efficacy.

For manufacturers, understanding EU regulations for drug device combination products is essential to achieve compliance, gain market approval, and deliver safe solutions to patients. In this blog, we’ll explore the EU regulatory landscape, the classification process, and how companies can successfully navigate compliance requirements.

What Are Drug Device Combination Products?

Drug device combination products are medical innovations that integrate both a device component and a medicinal substance. Some common examples include:

• Pre-filled inhalers used for respiratory conditions like asthma.

• Auto-injectors that deliver precise doses of drugs such as insulin or epinephrine.

• Drug-eluting stents designed to release medication directly at the site of implantation.

• Transdermal patches where the device controls the release of a medicinal drug.

The combination of device and drug offers improved therapeutic outcomes and greater convenience for patients. However, the dual nature of these products means that regulators must assess them under both medical device and pharmaceutical frameworks, making the approval process more complex.

The EU Regulatory Framework

The EU has established strict guidelines to ensure that combination products meet high standards of safety, quality, and performance. The regulations are primarily governed by:

1. Medical Device Regulation (MDR 2017/745) – Effective since May 2021, the MDR governs how devices, including those with an ancillary medicinal substance, are evaluated and certified in the EU.

2. Medicinal Product Directive (2001/83/EC) – This directive covers pharmaceutical products, ensuring drugs undergo rigorous testing for efficacy and safety.

The challenge lies in determining whether a product should be regulated primarily as a medicinal product with a device component, or as a medical device containing a medicinal substance. This classification impacts the approval pathway.

Classification of Combination Products

In the EU, the classification of combination products depends on the product’s primary mode of action (PMOA):

• If the drug is the primary mode of action, the product is treated as a medicinal product. For example, a chemotherapy drug delivered through an infusion pump would be classified as a medicinal product.

• If the device is the primary mode of action, the product is regulated as a medical device under MDR. For instance, a stent that mechanically keeps arteries open but also releases a drug is classified as a device with an ancillary drug.

Once classified, the manufacturer must follow the corresponding regulatory pathway. For medical device-led products, manufacturers must demonstrate safety and performance of both the device and the medicinal substance, often requiring consultation with a competent authority such as the European Medicines Agency (EMA).

Key Regulatory Requirements

When bringing a drug device combination product to the EU market, manufacturers must meet several important requirements:

1. Clinical Evaluation – Demonstrating the product’s safety and effectiveness through robust clinical data.

2. Risk Management – Assessing potential risks from both the device and drug components and implementing strategies to mitigate them.

3. Quality Management Systems (QMS) – Ensuring compliance with ISO 13485 for medical devices and Good Manufacturing Practices (GMP) for medicinal products.

4. Consultation Procedures – For device-led products containing medicinal substances, a notified body will consult with the EMA or a national medicines authority to evaluate the safety of the drug component.

5. Post-Market Surveillance (PMS) – Ongoing monitoring of the product’s performance after approval, including vigilance reporting and periodic safety updates.

These requirements ensure that combination products consistently deliver safe and effective results for patients throughout their lifecycle.

Challenges for Manufacturers

Bringing a drug device combination product to market in the EU is not without challenges. Some of the common hurdles include:

• Complex Documentation – Preparing technical files, clinical evaluations, and consultation reports can be resource-intensive.

• Changing Regulations – The transition from the Medical Devices Directive (MDD) to MDR introduced stricter requirements, creating additional compliance burdens.

• Cross-disciplinary Expertise – Companies need regulatory, engineering, and pharmaceutical expertise to navigate the approval process successfully.

• Longer Approval Timelines – The consultation process with both notified bodies and authorities can extend market access timelines compared to standard medical devices or drugs.

Despite these challenges, companies that successfully comply with EU regulations can gain a strong competitive advantage and establish trust with healthcare providers and patients.

Strategies for Compliance

To overcome regulatory complexities, manufacturers should adopt the following strategies:

1. Early Regulatory Planning – Engage with regulatory experts early in the development process to determine classification and regulatory pathways.

2. Robust Clinical Evidence – Invest in generating high-quality clinical data that supports both device safety and drug efficacy.

3. Strong Documentation Practices – Maintain comprehensive records that demonstrate compliance with MDR and medicinal product directives.

4. Partnership with Experts – Collaborating with specialized consultants, such as 3iconcept Medical Device Solutions, can help companies navigate regulatory requirements efficiently.

5. Ongoing Compliance Monitoring – Continuously track regulatory updates in the EU to ensure products remain compliant.

The Future of Combination Products in the EU

With the rise of personalized medicine, biologics, and advanced drug delivery systems, the demand for combination products is expected to grow significantly in the EU. Regulators are also expected to refine guidance to address innovative technologies such as digital health integration and smart drug delivery devices.

Manufacturers that stay ahead of regulatory changes and invest in innovation will be well-positioned to succeed in this evolving market.

Conclusion

EU regulations for drug device combination products are complex but essential to ensure patient safety and treatment effectiveness. By understanding the classification system, regulatory pathways, and compliance requirements, manufacturers can successfully bring these innovative products to market.

The key to success lies in early planning, strong clinical evidence, and expert guidance. With the right strategy, companies can not only achieve compliance but also unlock opportunities in one of the world’s most regulated and respected healthcare markets.